Autolus Therapeutics Ltd – (NASDAQ:AUTL) Receives Consensus Rating of “Buy” from Brokerages

Autolus Therapeutics Ltd – (NASDAQ:AUTL) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $33.33.

Several brokerages have commented on AUTL. William Blair reiterated a “buy” rating on shares of Autolus Therapeutics in a research note on Tuesday, September 3rd. Zacks Investment Research upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. Needham & Company LLC began coverage on shares of Autolus Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $26.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $24.00 price target on shares of Autolus Therapeutics in a research note on Thursday, September 12th. Finally, ValuEngine upgraded shares of Autolus Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

Hedge funds have recently made changes to their positions in the business. Exane Derivatives bought a new stake in shares of Autolus Therapeutics in the 2nd quarter worth about $50,000. Walleye Trading Advisors LLC bought a new stake in shares of Autolus Therapeutics in the 2nd quarter worth about $168,000. Walleye Trading LLC bought a new stake in shares of Autolus Therapeutics in the 2nd quarter worth about $170,000. Virtus ETF Advisers LLC increased its holdings in shares of Autolus Therapeutics by 105.3% in the 2nd quarter. Virtus ETF Advisers LLC now owns 17,311 shares of the company’s stock worth $279,000 after buying an additional 8,877 shares during the last quarter. Finally, TD Asset Management Inc. increased its holdings in shares of Autolus Therapeutics by 101.2% in the 2nd quarter. TD Asset Management Inc. now owns 21,229 shares of the company’s stock worth $342,000 after buying an additional 10,680 shares during the last quarter. Institutional investors and hedge funds own 51.64% of the company’s stock.

Shares of AUTL stock opened at $12.84 on Friday. The stock has a market cap of $488.17 million, a P/E ratio of -9.04 and a beta of 0.68. Autolus Therapeutics has a 52 week low of $9.50 and a 52 week high of $53.24. The company has a quick ratio of 13.12, a current ratio of 13.12 and a debt-to-equity ratio of 0.09. The company’s fifty day simple moving average is $12.22 and its two-hundred day simple moving average is $17.38.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.11. The company had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $2.00 million. On average, analysts anticipate that Autolus Therapeutics will post -3.14 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Featured Story: Intrinsic Value

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit